Vicapsys Life Sciences, Inc.

Vicapsys Life Sciences, Inc. is a holding company that develops and commercializes intellectual property rights related to encapsulated product candidates. The company was incorporated in Florida on July 8, 1997, as All Product Distribution Corp., changing its name to Phage Therapeutics International, Inc. on August 19, 1998, then to SSGI, Inc. on November 13, 2007, and finally to Vicapsys Life Sciences, Inc. on September 13, 2017. On September 13, 2017, the company also effected a 1-for-100 reverse stock split, increased its authorized common stock to 300,000,000 shares with a par value of $0.001 per share, and authorized 20,000,000 shares of "blank check" preferred stock with a par value of $0.001 per share. On December 22, 2017, ViCapsys, Inc. (VI) became a wholly owned subsidiary of Vicapsys Life Sciences, Inc. through a Share Exchange Agreement. Vicapsys Life Sciences, Inc. itself has no material assets or operations other than its interest in VI. The company's strategy focuses on developing and commercializing, globally, intellectual property such as patents and know-how for encapsulated product candidates. These candidates incorporate proprietary derivatives of the chemokine CXCL12 to create a zone of immunoprotection around cells, tissues, organs, and devices for therapeutic uses. The product line, VICAPSYN™, is applied to transplantation therapies and related stem-cell applications. The primary product candidate for treating Type 1 Diabetes (T1D) in transplantation therapy is an encapsulated human islet cell cluster designed to restore normal glucose control when implanted into a patient's peritoneal cavity. During research, the company and its academic researchers observed that transplanted islet clusters were entirely free of fibrotic encapsulation.